EA019923B1 - Композиции со сниженным образованием димеров - Google Patents

Композиции со сниженным образованием димеров Download PDF

Info

Publication number
EA019923B1
EA019923B1 EA201100865A EA201100865A EA019923B1 EA 019923 B1 EA019923 B1 EA 019923B1 EA 201100865 A EA201100865 A EA 201100865A EA 201100865 A EA201100865 A EA 201100865A EA 019923 B1 EA019923 B1 EA 019923B1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide
composition
peptides
syndrome
protein
Prior art date
Application number
EA201100865A
Other languages
English (en)
Russian (ru)
Other versions
EA201100865A1 (ru
Inventor
Родерик Питер Хэфнер
Пол Лэйдлер
Original Assignee
Серкешиа Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA019923(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Серкешиа Лимитед filed Critical Серкешиа Лимитед
Publication of EA201100865A1 publication Critical patent/EA201100865A1/ru
Publication of EA019923B1 publication Critical patent/EA019923B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201100865A 2008-11-28 2009-11-27 Композиции со сниженным образованием димеров EA019923B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821806.7A GB0821806D0 (en) 2008-11-28 2008-11-28 Compositions with reduced dimer formation
PCT/GB2009/002767 WO2010061193A2 (en) 2008-11-28 2009-11-27 Compositions with reduced dimer formation

Publications (2)

Publication Number Publication Date
EA201100865A1 EA201100865A1 (ru) 2011-12-30
EA019923B1 true EA019923B1 (ru) 2014-07-30

Family

ID=40262373

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100865A EA019923B1 (ru) 2008-11-28 2009-11-27 Композиции со сниженным образованием димеров

Country Status (21)

Country Link
US (3) US9180098B2 (xx)
EP (2) EP2649990A1 (xx)
JP (2) JP5612592B2 (xx)
KR (1) KR101669693B1 (xx)
CN (1) CN102227214B (xx)
AU (1) AU2009321358B2 (xx)
BR (1) BRPI0921541A2 (xx)
CA (1) CA2744587C (xx)
DK (1) DK2373293T3 (xx)
EA (1) EA019923B1 (xx)
ES (1) ES2427855T5 (xx)
GB (2) GB0821806D0 (xx)
HK (1) HK1161139A1 (xx)
HR (1) HRP20130933T1 (xx)
IL (1) IL213088A (xx)
MX (1) MX2011005530A (xx)
NZ (1) NZ593145A (xx)
PL (1) PL2373293T3 (xx)
SG (1) SG171438A1 (xx)
SI (1) SI2373293T1 (xx)
WO (1) WO2010061193A2 (xx)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US11266737B2 (en) 2013-09-25 2022-03-08 Aravax Pty Ltd Immunotherapeutic composition and uses thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2793939A1 (en) * 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
GB201301457D0 (en) * 2013-01-28 2013-03-13 Fluorogenics Ltd Freeze-dried composition
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
CN103656635B (zh) * 2013-12-05 2016-05-18 安徽润敏江生物科技有限公司 一种德国小蠊过敏原制剂的制备方法
CA2942122A1 (en) * 2014-04-10 2015-10-15 Asit Biotech S.A. Hsp-free allergen preparation
WO2016124661A1 (en) * 2015-02-04 2016-08-11 Universität Zürich Use of hla-b27 homodimers for cancer treatment
CA3004745A1 (en) 2015-11-12 2017-05-18 University Of Virginia Patent Foundation Compositions and methods for vas-occlusive contraception and reversal thereof
WO2017083511A1 (en) * 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-bcma polypeptides and proteins
CA3031605A1 (en) 2016-08-10 2018-02-15 Universitat Zurich Mhc class ia open conformers
CA3053451A1 (en) 2017-01-05 2018-07-12 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
EP3880273A4 (en) 2018-11-13 2022-08-24 Contraline, Inc. BIOMATERIALS DELIVERY SYSTEMS AND METHODS
EP4281565A1 (en) * 2021-01-22 2023-11-29 Syngenta Crop Protection AG Soybean engineered resistance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532A2 (en) * 1980-07-18 1982-01-27 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999034826A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US20080293624A1 (en) * 2000-08-31 2008-11-27 Chiron Corporation Stabilized FGF formulations containing reducing agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442212A (en) 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
JP2787162B2 (ja) * 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
AU650249B2 (en) * 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
HU220462B1 (hu) 1991-10-16 2002-02-28 Immulogic Pharmaceutical Corp. A Dermatophagoides nemzetség allergénjéből származó peptidek, ezeket tartalmazó gyógyszerkészítmények és eljárás házi poratka-érzékenység kimutatására
EP0636180A1 (en) 1992-04-09 1995-02-01 Immulogic Pharmaceutical Corporation T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
ES2260756T3 (es) 1992-12-31 2006-11-01 Heska Corporation Proteina y peptidos alergenicos de caspa de perro y sus usos.
NZ273815A (en) 1994-09-02 1999-05-28 Immulogic Pharma Corp Peptide compositions for treating protein allergies or autoimmune diseases containing at least two isolated and purified peptides
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
ATE414534T1 (de) * 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
ATE337014T1 (de) * 2002-03-15 2006-09-15 Natimmune As Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
WO2003093299A2 (en) 2002-05-06 2003-11-13 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
AU2004288854B2 (en) 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
JP5044829B2 (ja) 2003-12-31 2012-10-10 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体のための医薬組成物
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
WO2006083906A2 (en) 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic phscn-peptide
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
CA2624503A1 (en) * 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009022154A2 (en) 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532A2 (en) * 1980-07-18 1982-01-27 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999034826A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
US20080293624A1 (en) * 2000-08-31 2008-11-27 Chiron Corporation Stabilized FGF formulations containing reducing agents
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US11980658B2 (en) 2012-10-30 2024-05-14 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US11266737B2 (en) 2013-09-25 2022-03-08 Aravax Pty Ltd Immunotherapeutic composition and uses thereof
US11986522B2 (en) 2013-09-25 2024-05-21 Ara Vax Pty Ltd Immunotherapeutic composition and uses thereof

Also Published As

Publication number Publication date
US20160367660A1 (en) 2016-12-22
US20160038587A1 (en) 2016-02-11
GB0821806D0 (en) 2009-01-07
DK2373293T3 (da) 2013-10-07
JP5612592B2 (ja) 2014-10-22
NZ593145A (en) 2013-01-25
WO2010061193A3 (en) 2011-06-23
JP2012510457A (ja) 2012-05-10
EP2373293B1 (en) 2013-07-31
SG171438A1 (en) 2011-07-28
US9375470B2 (en) 2016-06-28
KR20110092329A (ko) 2011-08-17
ES2427855T5 (es) 2016-06-28
IL213088A (en) 2017-01-31
EA201100865A1 (ru) 2011-12-30
GB2479515A (en) 2011-10-12
BRPI0921541A2 (pt) 2016-04-26
AU2009321358A1 (en) 2011-06-30
SI2373293T1 (sl) 2013-11-29
EP2373293B2 (en) 2016-06-01
MX2011005530A (es) 2011-06-06
IL213088A0 (en) 2011-07-31
WO2010061193A2 (en) 2010-06-03
JP2015057383A (ja) 2015-03-26
CA2744587C (en) 2020-07-14
GB201114575D0 (en) 2011-10-05
HRP20130933T1 (hr) 2013-11-08
US20120014978A1 (en) 2012-01-19
KR101669693B1 (ko) 2016-11-09
PL2373293T3 (pl) 2013-12-31
EP2649990A1 (en) 2013-10-16
GB2479515B (en) 2013-05-22
ES2427855T3 (es) 2013-11-04
US9180098B2 (en) 2015-11-10
EP2373293B8 (en) 2013-09-18
JP5905942B2 (ja) 2016-04-20
EP2373293A2 (en) 2011-10-12
CN102227214A (zh) 2011-10-26
CN102227214B (zh) 2015-02-18
AU2009321358B2 (en) 2015-06-18
HK1161139A1 (en) 2012-08-24
CA2744587A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
EA019923B1 (ru) Композиции со сниженным образованием димеров
ES2402956T3 (es) Péptido con formación de dímeros reducida
CZ20021186A3 (cs) Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
ES2749977T3 (es) Composiciones de proteínas terapéuticas que tienen inmunogenia reducida y/o eficacia mejorada
de Coaña et al. Molecular cloning and characterization of Cup a 4, a new allergen from Cupressus arizonica
Liu et al. Purification and characterization of protamine, the allergen from the milt of large yellow croaker (Pseudosciaena crocea), and its components
US11013781B2 (en) Peptide combinations and uses thereof for treating grass allergy
WO2017203057A1 (en) Immunogenic proteins and fragments thereof from allergenic mites
Egger et al. Development of recombinant allergens for diagnosis and therapy
Nikolić et al. Effect of malondialdehyde on the ovalbumin structure and its interactions with T84 epithelial cells
AU2015227499B2 (en) Compositions with reduced dimer formation
ARAKAWA et al. Effect of amino-terminal processing by Staphylococcus aureus V-8 protease on activity and structure of recombinant human interferon-γ
CN102791289B (zh) 因脯氨酸残基突变而具有降低变应原性的真禾本科第5组变应原的变体
BRPI0313613B1 (pt) variantes do principal alérgeno phl p 1 de capim-timóteo, suas formas de enovelamento lm e hm, seus usos e seus processos de preparação e de purificação, molécula de dna, vetor de expressão de dna recombinante e seu uso, e composições farmacêuticas
Shahrokh Developing pharmaceutical protein formulations: Assumptions and analytical tools
EP1479689A1 (en) Peptide complex

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU